{
    "nctId": "NCT06111417",
    "briefTitle": "Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners",
    "officialTitle": "Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Compare the results obtained with an ultra-rapid kit BRCA1/2 with those obtained with the current gold standard, by checking the sensitivity, specificity and the rate of patients correctly classified for BRCA1 and 2 status",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic management of breast cancer.\n* The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.\n* Diagnosis of the disease \u2264 6 months\n* The patient must be affiliated to the social security system.\n\nExclusion Criteria:\n\n* Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires\n* Patients who do not have an email address and/or do not have internet access or tools to connect to the internet\n* Women who are pregnant, may become pregnant or are breast-feeding\n* Persons deprived of their liberty or under guardianship (including curatorship)\n* Inability to undergo trial monitoring for geographical, social or psychological reasons.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}